Adicet opens enrollment for adi-001 phase 1 clinical trial in autoimmune diseases

Redwood city, calif. & boston--(business wire)--adicet bio, inc. (nasdaq: acet), a clinical stage biotechnology company discovering and developing allogeneic gamma delta t cell therapies for autoimmune diseases and cancer, today announced the opening of enrollment for the phase 1 clinical trial evaluating adi-001 in autoimmune diseases. “the favorable safety profile, cellular kinetics and b cell depletion in peripheral blood and secondary lymphoid tissue demonstrated with adi-001 clinical exper.
ACET Ratings Summary
ACET Quant Ranking